OPORF Stock - hVIVO plc
Unlock GoAI Insights for OPORF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $62.73M | $56.04M | $50.70M | $36.86M | $20.60M |
| Gross Profit | $62.73M | $13.04M | $9.07M | $35.90M | $19.88M |
| Gross Margin | 100.0% | 23.3% | 17.9% | 97.4% | 96.5% |
| Operating Income | $12.86M | $10.10M | $6.02M | $590,000 | $-10,259,000 |
| Net Income | $10.65M | $16.11M | $-776,000 | $-74,000 | $-10,791,000 |
| Net Margin | 17.0% | 28.8% | -1.5% | -0.2% | -52.4% |
| EPS | $0.02 | $0.02 | $-0.00 | $-0.00 | $-0.02 |
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides preclinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
Visit WebsiteEarnings History & Surprises
OPORFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 8, 2026 | — | — | — | — |
Q2 2025 | Apr 7, 2025 | — | $0.01 | — | — |
Q3 2024 | Sep 10, 2024 | — | $0.01 | — | — |
Q2 2024 | May 13, 2024 | $0.01 | $0.02 | +156.9% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | — | $0.01 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.00 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.00 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.01 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.02 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.02 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.02 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.07 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-2.55 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.01 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.01 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.00 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.00 | — | — |
Q4 2015 | Dec 31, 2015 | — | $0.00 | — | — |
Latest News
Frequently Asked Questions about OPORF
What is OPORF's current stock price?
What is the analyst price target for OPORF?
What sector is hVIVO plc in?
What is OPORF's market cap?
Does OPORF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OPORF for comparison